{"entity":{"id":"nct05594797","kind":"trial","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","aka":[],"tldr":"A phase 2 trial of Human BCMA Targeted T Cells Injection in multiple myeloma, run by Hrain Biotechnology Co., Ltd., now recruiting.","summary":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM is a phase 2 interventional study registered as NCT05594797 by Hrain Biotechnology Co., Ltd., with 100 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-07-31. Interventions recorded: Human BCMA Targeted T Cells Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05594797","url":"https://clinicaltrials.gov/study/NCT05594797"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05594797","phase":"2","setting":"A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection Therapy for Relapsed/Refractory Multiple Myeloma","sponsor":"Hrain Biotechnology Co., Ltd.","started":"2022-07-12","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05594797/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}]}}